BTK and neoplasm: The ibrutinib-mediated modulation of the TME involves disrupting oncogenic signaling axes and inhibiting growth-supportive cytokines and growth factors, highlighting the dynamic interplay between the TME and tumor cells in driving resistance mechanisms to BTK inhibitors [50,58].